SCHEMBL5376663

SCHEMBL5376663

Cc1ccsc1C=C1C(=O)Nc2ccc(NCC(O)CO)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 7/20 0.43
MEN1 O00255 2/20 0.43
KMT2A Q03164 2/20 0.43
NPC1 O15118 1/20 0.43
ALDH1A1 P00352 1/20 0.43
MAPT P10636 1/20 0.43
RAB9A P51151 1/20 0.43
PDPK1 O15530 2/20 0.42
GSK3B P49841 4/20 0.39
LRRK2 Q5S007 1/20 0.39
TLK2 Q86UE8 1/20 0.39
KDR P35968 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC4 P56524 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC7 Q8WUI4 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5369945 0.81 NTRK1 (0.43) NTRK1KMT2AALDH1A1MAPTPDPK1
SCHEMBL7493570 0.81 NTRK1 (0.64) NTRK1MEN1KMT2ANPC1MAPT
SCHEMBL5370007 0.80 RET (0.42) NTRK1MEN1KMT2ANPC1ALDH1A1
SCHEMBL5361229 0.79 AKT2 (0.59) PDPK1GSK3B
SCHEMBL5358278 0.78 MEN1 (0.46) MEN1KMT2ANPC1ALDH1A1MAPT
SCHEMBL5366906 0.78 AKT2 (0.48) MEN1KMT2APDPK1GSK3BTLK2
SCHEMBL5376707 0.77 PDPK1 (0.68) NTRK1MEN1KMT2ANPC1ALDH1A1
SCHEMBL5367043 0.77 NTRK1 (0.66) NTRK1PDPK1TLK2
SCHEMBL6297819 0.76 LRRK2 (0.60) LRRK2
SCHEMBL6297823 0.76 LRRK2 (0.60) LRRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed
EP-1247803-A2 Indolinone compounds suitable for modulation of protein kinases Sugen, Inc. (US) 2002-10-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK NTRK1 223/4885MEN1 3855/4885KMT2A 4060/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.